Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CFO Sells 10,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $7.68, for a total value of $76,800.00. Following the transaction, the chief financial officer now owns 19,738 shares in the company, valued at approximately $151,587.84. This represents a 33.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Zynex Stock Performance

NASDAQ:ZYXI opened at $7.99 on Thursday. The firm has a 50-day moving average of $8.09 and a two-hundred day moving average of $8.17. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The stock has a market cap of $254.48 million, a P/E ratio of 53.27 and a beta of 0.54. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Investment Partners Asset Management Inc. raised its stake in shares of Zynex by 10.4% in the 4th quarter. Investment Partners Asset Management Inc. now owns 12,942 shares of the company’s stock valued at $104,000 after purchasing an additional 1,220 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Zynex by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company’s stock worth $334,000 after purchasing an additional 1,318 shares during the last quarter. Gladius Capital Management LP grew its stake in Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after buying an additional 1,742 shares during the last quarter. Jane Street Group LLC increased its position in Zynex by 8.9% in the third quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock worth $192,000 after buying an additional 1,929 shares during the period. Finally, R Squared Ltd bought a new stake in Zynex in the fourth quarter valued at $26,000. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Zynex in a research report on Friday, December 6th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.